© Reuters. 
By Peter Nurse
Investing.com -- Shares in center of attention in premarket switch on Wednesday, March 1st. Please refresh for updates.
-
Kohl's (NYSE:KSS) stock fell 7.3% after the division store chain reported a vacation-quarter loss and forecast beefy-year profit below expectations as possibilities tightened their spending.
-
Lowe’s (NYSE:LOW) stock rose 0.3% after the house improvement retailer beat quarterly profit expectations, but equipped up a disappointing beefy-year gross sales forecast, as soaring costs goal customers to cease spending on house-connected projects.
-
Rivian (NASDAQ:RIVN) stock slumped 8.6% after the electrical vehicle producer forecast 2023 manufacturing effectively below estimates, and launched a recall of more than 12,700 vehicles.
-
Tesla (NASDAQ:TSLA) stock rose 0.4% earlier than an investor day, and with the electrical car producer space to verify a brand unique manufacturing facility in Mexico after inserting a water deal.
-
AMC Leisure (NYSE:AMC) fell 6.9% after the cinema chain recorded a more than 15% fall in fourth-quarter income, including that the box pronounce of job is yet to come to pre-pandemic norms.
-
Novavax (NASDAQ:NVAX) stock slumped 27.8% after the drugmaker stated there's significant uncertainty spherical its 2023 income and launched plans to gash spending earlier than the autumn vaccination marketing campaign.
-
Buck Tree (NASDAQ:DLTR) stock fell 3.2% after the nick note chain forecast beefy-year profit below expectations as possibilities reined in discretionary spending.
-
Procter & Gamble (NYSE:PG) stock rose 1.3% after UBS upgraded its stance on the user goods huge to ‘buy’ from ‘neutral’, saying the shares can rally fair about 20% from recent phases.
-
Overall Motors (NYSE:GM) stock rose 0.9% after the auto huge launched it turned into chopping hundreds of high-stage jobs because it appears to be like to be to nick costs and streamline operations.
-
Sarepta Therapeutics (NASDAQ:SRPT) stock rose 17.1% after Morgan Stanley upgraded its stance on the biotech to ‘overweight’ from ‘equal-weight’, saying its shares can rally more than 50%.
